Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Zaicom MMC appoints new medical writer

August 17, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Katharine Peregrín, Zaicom MMC

Comms agency Zaicom MMC, part of the Zaicom International group of companies, has appointed Katharine Peregrín as a medical writer.  …
Appointment

Novartis eye drug succeeds in Phase III trial

August 16, 2012 Sales and Marketing FDA, Novartis, Ocriplasmin, Roche, VMA

Novartis has posted positive results for its investigational eye drug ocriplasmin. The Phase III study found that ocriplasmin significantly resolved …
News

The number one reason for a failed project

August 16, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Communication, Failed project, Les Rose, clinical trials

There was once a company that had an amusing form of words for admonishing people. It went something like this: …
Feature

Boehringer posts strong financials

August 16, 2012 Sales and Marketing AMNOG, Boehringer, COPD, Spiriva

Boehringer Ingelheim has seen steady growth in the first half of 2012, but warns that the next six months may …
News

Diabetes prescriptions jump by 50% in England

August 15, 2012 Sales and Marketing Humalog, Januvia, NHS, diabetes, spending

Diabetes prescriptions in England have for the first time topped 40 million this year, a rise of nearly 50% compared …
News

GSK sheds Australian generics unit for £172m

August 15, 2012 Sales and Marketing Aspen Global, GSK, generics

GlaxoSmithKline has divested the majority of its Australian generics unit to Aspen Global, a firm it partly owns. The South …
News

Genus reprimanded for ‘sexual and titillating’ advert

August 15, 2012 Sales and Marketing ABPI, Genus, PMCPA, breach, eczema

Genus has been found in breach of the ABPI Code after using a sexually charged image for the promotion of …
News

Smoke and fire in J&J Code breach

August 15, 2012 Sales and Marketing Champix, J&J, JJ, Johnson and Johnson, PMCPA, Pfizer

Johnson & Johnson has been censured for breaking the ABPI Code of Practice in printed information about its smoking cessation …
News

Elan to spin off drug discovery arm

August 14, 2012 Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis

Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …
News

New Avastin data could be bad news for Lucentis

August 14, 2012 Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
News

Astellas Pharma Europe appoints new senior director

August 14, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Susan Wood

Astellas Pharma Europe has appointed Dr Susan Wood as senior director, Market Access. Formerly senior brand director of APEL’s Pain Management …
Appointment

Pfizer pays $250m for OTC Nexium rights

August 14, 2012 Sales and Marketing AstraZeneca, EMA, FDA, Nexium, OTC, Pfizer

Pfizer will pay $250 million to AstraZeneca in order to gain the rights to sell an over-the-counter form of the …
News

Avastin sees success in brain cancer trial

August 13, 2012 Research and Development, Sales and Marketing R&D, avastin, brain cancer

A late-stage study has shown that Roche’s oncology drug Avastin, when added to standard therapy, can help people with brain …
News

Torisel-Avastin combo fails in kidney cancer

August 13, 2012 Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc

Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
News

Lucentis gains new licence in the US

August 13, 2012 Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD

Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026